Losonsky G A, Tacket C O, Wasserman S S, Kaper J B, Levine M M
Department of Pediatrics, University of Maryland School of Medicine, Baltimore 21201.
Infect Immun. 1993 Feb;61(2):729-33. doi: 10.1128/iai.61.2.729-733.1993.
Peripheral blood immunoglobulin A antibody-secreting-cell (ASC) responses are thought to reflect the mucosal immune response to locally presented antigens. We evaluated the ASC response to cholera toxin (CT) and Inaba lipopolysaccharide (LPS) in 26 North American volunteers following immunization with a single oral dose of live attenuated Vibrio cholerae O1 vaccine strain CVD 103-HgR and again upon homologous wild-type challenge with V. cholerae classical Inaba 569B. Challenge occurred at either 7, 30, or 180 days after vaccination. The CT and LPS ASC responses of volunteers following vaccination (83 and 55%, respectively) were similar in magnitude and frequency to those of unvaccinated controls following wild-type challenge (80 and 60%, respectively [0.1 < or = P < or = 0.9]). The responses were primarily immunoglobulin A. Vaccinated volunteers challenged within 30 days of vaccination had reduced or nondetectable CT and LPS ASC responses. Challenge at 6 months resulted in a heightened ASC response to LPS, confirming the existence of mucosal memory. ASC responses to CT upon challenge at 6 months were detectable but not different from that seen following primary immunization, suggesting that secondary ASC responses to different antigens from a single vaccine operate independently. In spite of these variable ASC responses, the vaccine efficacy was 100% following challenge for all vaccinees. V. cholerae-specific ASC responses following antigenic reexposure gave information on the presence of mucosal B memory cells but did not correlate with protective immunity. As such, these ASC assays will have limited usefulness for evaluating vaccine responders in vaccine field trials in cholera-endemic areas where prior V. cholerae O1 exposure is unknown.
外周血免疫球蛋白A抗体分泌细胞(ASC)反应被认为反映了对局部呈现抗原的黏膜免疫反应。我们评估了26名北美志愿者在单次口服活减毒霍乱弧菌O1疫苗株CVD 103-HgR免疫后以及再次用霍乱弧菌古典生物型稻叶569B进行同源野生型攻击后,对霍乱毒素(CT)和稻叶脂多糖(LPS)的ASC反应。攻击在接种疫苗后的7天、30天或180天进行。接种疫苗后志愿者的CT和LPS的ASC反应(分别为83%和55%)在幅度和频率上与野生型攻击后未接种疫苗的对照者的反应相似(分别为80%和60%[0.1≤P≤0.9])。反应主要为免疫球蛋白A。在接种疫苗后30天内受到攻击的接种疫苗志愿者的CT和LPS的ASC反应降低或无法检测到。6个月时的攻击导致对LPS的ASC反应增强,证实了黏膜记忆的存在。6个月时攻击后对CT的ASC反应可检测到,但与初次免疫后所见反应无差异,这表明来自单一疫苗对不同抗原的二次ASC反应是独立运作的。尽管这些ASC反应存在差异,但所有疫苗接种者在攻击后的疫苗效力均为100%。抗原再次暴露后霍乱弧菌特异性ASC反应提供了有关黏膜B记忆细胞存在的信息,但与保护性免疫无关。因此,在霍乱流行地区,在先前霍乱弧菌O1暴露情况未知的疫苗现场试验中,这些ASC检测对于评估疫苗反应者的作用有限。